DT
CLDX icon

Diversified Trust’s Celldex Therapeutics CLDX Stock Holding History

Diversified Trust’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
31,330
+24,309
+346% +$785K 0.02% 453
2026
Q1 		$223K Buy
+7,021
New +$191K ﹤0.01% 944
2013
Q4 		$280K Buy
772
+18
+2% +$6.93K 0.03% 411
2013
Q3 		$401K Buy
+754
New +$259K 0.04% 353

Other funds holding CLDX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Diversified Trust's CLDX Position: Q2 2026 in Review

Diversified Trust increased its Celldex Therapeutics (CLDX) stake by 346% in Q2 2026, buying an estimated $785K and bringing the position to 31,330 shares worth $1.17M. The position accounts for 0.02% of the portfolio, ranked #453.

Diversified Trust first reported a position in CLDX in Q3 2013 and has held it in 4 quarters since. 16 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Diversified Trust held 31,330 shares of Celldex Therapeutics worth $1.17M as of Q2 2026.
  • Diversified Trust bought 24,309 Celldex Therapeutics shares in Q2 2026, an estimated $785K.
  • Celldex Therapeutics made up 0.02% of Diversified Trust's portfolio in Q2 2026, its #453 holding.
  • Diversified Trust first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 4 quarters since.
  • 16 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Diversified Trust's 13F filing for Q2 2026, filed 17 Jul 2026.